With more than a decade since the first FDA biosim approval, strong launches of biologic copies of AbbVie’s Humira, J&J’s Stelara and Regeneron/Bayer’s Eylea are shifting a narrative once focused on lagging uptake of the category in the United States.
Source: FiercePharma
